The human adenovirus 289R E1A transactivating protein can stimulate transcription from a variety of promoters by apparently complexing with both DNA-specific recognition site transcription factors, e.g., ATF-2, SP1, and USF (19, 20) , and components of the basal transcription initiation complex (1, 6, 7, 13, 17, 25, 38) . Through the formation of such proteinprotein interactions, E1A seems to mediate transcription without binding to DNA. The 48-amino-acid conserved region 3 (CR3) of E1A, which is responsible for mediating transactivation (29) , appears to target several proteins of the transcription initiation complex (1, 6, 7, 13, 17, 25, 38) . CR3 contains a Cys-4 zinc finger which binds to the TATA box-binding protein, TBP (7) . Mutations within the CR3 zinc finger region (residues 147 to 177) that eliminate TBP binding correlate with a loss of E1A transactivation function (7) . In addition, in vitro studies have revealed an apparent requirement for TBP-associated factors (TAFs) in E1A-mediated stimulation of transcription (38) . In these studies, it was found that TBP could not functionally replace purified TFIID, the complex containing TBP and TAFs (for a recent review, see reference 2). Indeed, our recent studies demonstrated that Drosophila TAF II 110 and human TAF II 250 complex with the CR3 region of E1A (6, 25) . In addition, human TAF II 55 has also been shown to bind CR3 (4) . Significantly, interactions between TAFs and other activators have been shown to be essential for modulating transcription both in vitro (3) and in vivo (24, 32) .
We previously reported that the CR3 transactivation domain of E1A binds to the C terminus of Drosophila TAF II 110 (dTAF II 110) (6, 24) . Most recently, hTAF II 135, the human homolog of dTAF II 110, has been cloned (26, 33) . Because modulation of transcription by E1A has been studied in mammalian systems, it was important to determine whether there exists a corresponding E1A-hTAF II 135 interaction. To examine this question, binding studies using glutathione S-transferase fusion proteins and [
35 S]methionine-labeled proteins generated by in vitro transcription and translation were performed. GST fusion proteins GST-hTAF II 135 (27) , GST-E1A (121-223) (6) , and GST-p50 (gift from I. Verma, Salk Institute) were purified essentially as previously described (6) . For in vitro transcription and translation (Promega) of hTAF II 135 constructs, the T7 RNA polymerase promoter in pET21d or pXJ40 was utilized. Quantitation of the amount of [
35 S]methionine incorporated was determined by analyzing aliquots of the translation reactions by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis and measuring the radioactivity in resolved bands corresponding to the specific hTAF II 135 polypeptide with a Molecular Dynamics PhosphorImager. The full-length hTAF II 135 cDNA (pXJ40-hTAF II 135 (1-1083) has been described previously (26) . A ClaI digest of pXJ40-hTAF II 135(1-1083) generated hTAF II 135⌬C248. A series of plasmids encoding hTAF II 135 C-terminal constructs (pET21d578R, pET21d⌬N299, pET21d⌬N367, pET21d⌬N433, and pET21d⌬N473) were generated by PCR cloning with pAT6-hTAF II 135(372-1083), which encodes the C-terminal 711 amino acids of hTAF II 135, as the DNA template; the 5Ј primers contained an appended EcoRI site, and the 3Ј primer contained the hTAF II 135 stop codon and an appended NotI site. The gel-purified inserts were ligated into EcoRI and NotI sites of pET21d. hTAF II 135 polypeptide carboxyl-terminal deletions were produced by utilizing natural restriction sites within the hTAF II 135 DNA sequences. Specifically, pET21d578R was digested with ClaI to produce hTAF II 135 polypeptide ⌬C248, with PvuI to produce ⌬C75, and with AvaI to produce ⌬C45. The E1A constructs (6, 17) , BBV-13S, BBV-12S, BBV-E1A (⌬140-146) , BBV-E1A (⌬147-153) , BBV-E1A (⌬154-159) , BBV-E1A (⌬160-168) , BBV-E1A (⌬169-174) , BBV-E1A (⌬175-179) , and BBV-E1A (⌬180-188) , were used in in vitro transcription and translation. The assay used to analyze the binding of in vitrotranslated proteins to the GST fusion proteins was previously described (25) . To normalize the input [ 35 S]methionine incorporated in each binding reaction, an adjusted volume of in vitro-translated hTAF II 135 polypeptide was used. Bound proteins were eluted from the glutathione-agarose beads by boiling in Laemmli buffer and resolved on an SDS-10 to 20% gradient polyacrylamide gel.
As shown in Fig. 1A , in vitro-translated full-length hTAF II 135 is able to bind to the GST-E1A (121-223) fusion protein which includes the CR3 transactivation domain of E1A. Since the C-terminal coding region of dTAF II 110 is critical for binding E1A (25) and exhibits extensive homology (52% iden-tity) with hTAF II 135 (Fig. 2) , we reasoned that the C terminus of hTAF II 135 might also bind E1A. Therefore, we tested the ability of GST-E1A to bind an hTAF II 135 deletion mutant (hTAF II 135⌬C248) whose DNA had had 248 codons removed from the region encoding the C terminus of fulllength hTAF II 135. As seen in Fig. 1A , GST-E1A (121-223) completely failed to bind hTAF II 135⌬C248. This suggested that the C terminus is the only region of hTAF II 135 required to bind E1A.
In order to confirm that the C terminus of hTAF II 135 binds directly to the CR3 transactivation domain, a GST fusion protein containing the C-terminal 583 amino acids of hTAF II 135 was tested for its ability to bind in vitro-translated E1A proteins. As shown in Fig. 1B , the hTAF II 135 C-terminal fusion protein exhibited strong binding to the 289R E1A protein which contains CR3 but only negligible binding to the 243R E1A protein which is identical to the larger E1A protein except that it lacks CR3. To examine which regions of the E1A CR3 transactivation domain are needed to mediate this E1A-hTAF II 135 interaction, a series of E1A mutants with sequential amino acid deletions spanning the entire CR3 transactivation domain (6) were translated in vitro and assayed for binding to the GST-hTAF II 135 C-terminal fusion protein. The results, which are summarized in Fig. 3 , indicate that deleting either of the regions of CR3 which flank the C4 zinc finger significantly reduces binding to the hTAF II 135 C-terminal fusion protein. Relative to the C4 zinc finger, the more distal flanking sequences (residues 140 to 146 or 180 to 188) appeared more sensitive to mutation than did the more proximal flanking sequences (residues 147 to 153 or 175 to 179), producing a bigradient of decreasing hTAF II 135 binding activity. Deletions within the Cys-4 Zn finger region (residues 147 to 177) of CR3 had no major effect on hTAF II 135 binding. Interestingly, the Cys-4 Zn finger region has been shown to bind hTBP and is postulated to bind a limiting cellular transcription factor as well (7) . Importantly, E1A proteins with mutations in the CR3 regions flanking the Cys-4 Zn finger are not only defective in binding hTAF II 135 but also are defective in stimulating transcription (7, 23, 35) . These results suggest that CR3, and in particular the regions which flank the Cys-4 Zn finger, might contribute to the recruitment of E1A to the basal promoter through interactions with the hTAF II 135 C terminus.
To fine map the C-terminal region of hTAF II 135 that ineracts with the CR3 region of E1A, in vitro-translated hTAF II 135 polypeptides generated from deletion constructs were tested for binding to GST-E1A . For each hTAF II 135 deletion mutant, a polypeptide of the expected length was synthesized as the major product of the in vitro translation reaction (data not shown). As expected, the 578R C-terminal fragment of hTAF II 135 was able to bind GST-E1A (121-223) but not GST protein alone or GST-p50, which includes the p50 subunit of NF-B ( Fig. 4A ; compare lane 4 with lanes 2 and 3). A series of N-terminal deletions generated from the 578R C-terminal coding region (⌬N299, ⌬N367, ⌬N433, and ⌬N473) were all capable of interacting with GST-E1A (Fig. 4A, lanes 5 to 12) . Importantly, the fact that binding still occurs with ⌬N473 indicates that an E1A CR3 binding site is contained within the last 105-amino-acid stretch of hTAF II 135 (summarized in Fig. 4B ).
A series of C-terminal deletions (⌬C248, ⌬C75, and ⌬C45) generated from the 578R hTAF II 135 construct confirmed that the extreme C terminus of hTAF II 135 is necessary for binding CR3. Each of these C-terminal deletions abrogated binding to GST-E1A (Fig. 4A, lanes 13 to 19) . Eliminating the last 248 residues (⌬C248) was expected to abrogate binding to E1A (Fig. 1A) . However, failure of the shorter C-terminal deletions of 75 (⌬C75) and 45 (⌬C45) residues to bind E1A clearly substantiated the importance of the last 105 amino acids of hTAF II 135 for interacting with E1A CR3 (summarized in Fig.  4B ).
It was important to demonstrate that binding of CR3 to the C terminus of hTAF II 135 can occur in vivo and hence may be significant to E1A-mediated transactivation. We reasoned that if the CR3 region targets the C terminus of hTAF II 135, then E1A transactivation might be blocked in the presence of a polypeptide containing the C terminus of hTAF II 135. Transfections employing the calcium phosphate precipitation method (9, 10) were performed in duplicate in NIH 3T3 cells, and the total amount of plasmid DNA used per transfection (27 g) was equalized by the addition of hTAF II 135 parental plasmid lacking insert. Cell extracts were assayed 48 h posttransfection for reporter chloramphenicol acetyltransferase (CAT) (26) . As shown in Fig. 5A , the ability of pSK-E1A (2 g) to transactivate the E3 promoter was dramatically inhibited (ϳ75%) with the least amount of transfected phTAF135-279C (1 g). Inhibition of E1A transactivation to a level approaching basal levels was achieved with slightly higher concentrations of transfected phTAF135-279C. By contrast, a 347-amino-acid N-terminal cDNA-derived fragment (encoded by phTAF135-347N) (26) which does not bind to E1A but which is expressed in transfected cells (data not shown) did not block E1A transactivation (Fig. 5B) . Nor was E1A transactivation inhibited by the Gal4 DNA binding domain (37), a non-TAF polypeptide, which does not interact with E1A (20) . Conversely, the C-terminal hTAF II 135 fragment did not affect transcriptional stimulation mediated by the activation domain of VP16 (18, 30) , the herpes virus transactivating protein for which there is no apparent interaction with hTAF II 135 (15) (data not shown). Thus, the in vivo interaction between the C terminus of hTAF II 135 and E1A appears to be specific. The C-terminal fragment of hTAF II 135 most likely inhibited E1A transactivation in vivo by directly targeting CR3. To show that endogenous E1A can interact with the C terminus of hTAF II 135, nuclear extract (72 g) prepared from E1A-expressing Ad5-transformed cells (21) was bound to GST or GST-hTAF II 135 (5 g). Bound proteins were released and fractionated on an SDS-10 to 20% gradient polyacrylamide gel, transferred onto an Immobilon-P membrane (Millipore) and probed with E1A-specific mouse monoclonal antibody M73 (11) . When nuclear extract was incubated with the GSThTAF II 135 C-terminal fusion protein, only the 289R E1A protein containing CR3 complexed with the C terminus of hTAF II 135 (Fig. 6) . By contrast, the 243R E1A protein, which is identical to 289R E1A except that it lacks CR3, essentially failed to interact with the C terminus of hTAF II 135. Taken together, these results strongly suggest that E1A-mediated transactivation involves a specific interaction between CR3 and the C terminus of hTAF II 135.
In this study, we have demonstrated that residues within the extreme C terminus of hTAF II 135 are able to bind to the CR3 activation domain of E1A and block its ability to stimulate transcription of an E1A-inducible promoter. Our results indicate that no region other than the 105-amino-acid C terminus of full-length hTAF II 135 is able to interact with E1A. The predominant feature of the 105-amino-acid C terminus of TAF II 135 is a serine-, glycine-, and threonine-rich region flanked by stretches of acidic and basic residues (Fig. 4B) . The corresponding C terminus of Drosophila dTAF II 110, which was also found to be important for binding 289R E1A (6, 25) , shares 57% identity with hTAF II 135 (26) . Significantly, two other viral transactivators, HPV-16 E7 and simian virus 40 T antigen, which can bind to the C terminus of dTAF II 110 (25) can also bind the C terminus of hTAF II 135 (unpublished results). Moreover, we anticipate that each of these three oncoproteins will bind to the human B cell-specific hTAF II 105, since the sequence of this partially cloned TAF revealed that its C terminus is highly homologous to that of hTAF II 135 (5, 26) .
Our finding that the CR3 region is the only segment of E1A which contacts the C terminus of hTAF II 135 is consistent with growing evidence suggesting that activation domains function, in part, by contacting distinct TAFs (34) . Other factors which have been shown to bind CR3 are hTAF II 250 (6), hTAF II 55 (4), TBP (7, 13, 17) , and certain DNA-specific recognition site transcription factors that include ATF-2, SP1, and USF (19, 20) . Significantly, CR3 mutant proteins which fail to bind one or more of these cellular transcription factors are also defective in E1A transactivation (7, 23, 35) . While the details of how each of these transcription factors interacts with CR3 need to be elucidated, an analysis of CR3 mutants implies that these factors do not all recognize the same portion of E1A. Interestingly, TBP appears to bind to the Cys-4 zinc finger of CR3 (7), whereas hTAF II 135 appears to interact with regions of CR3 flanking the Cys-4 zinc finger, as suggested in this study. It is of interest that a limiting cellular factor (CR3BP/LMP1), as defined by genetic analysis, is also critical in E1A activation (7) .
The proposal that an interaction between the C terminus of hTAF II 135 and the CR3 region of E1A is important for E1A activation is in concordance with the observation that TAFs within the TFIID complex are needed to support E1A-mediated transactivation (38) . In this study, E1A-mediated transactivation in vivo was dramatically inhibited by coexpressing the C-terminal polypeptide of hTAF II 135. This finding is significant in that it is the first demonstration of how transcriptional stimulation in vivo can be blocked by expressing the portion of a mammalian TAF which contains the binding site for a specific activator. In this study, formation of an hTAF II 135 polypeptide-E1A complex likely sequesters CR3 and prevents it from targeting components of the transcription initiation complex, including endogenous TAF II 135. However, we cannot completely rule out the possibility that the C-terminal fragment of hTAF II 135 may titrate out an additional factor that is necessary for hTAF II 135-dependent activation. The specificity of the E1A-hTAF II 135 C-terminal polypeptide interaction was demonstrated by the failure of a N-terminal region of hTAF II 135 to either bind E1A or to inhibit E1A-mediated transactivation. In addition, we found that coexpressing the C-terminal polypeptide of hTAF II 135 did not prevent transcriptional stimulation by the acidic activator Gal4-VP16, which has been shown to bind a different human TAF, hTAF II 31 (15) .
Recently, hTAF II 135 has been shown to interact with two other TAFs, hTAF II 250 (27) and hTAF II 20/15 (12, 27) , as well as with the transcription factor TFIIA (2). TFIIA stabilizes TFIID binding to the promoter (14, 22) and perhaps induces a conformational change in TFIID (16, 28) . Since hTAF II 135 is also able to bind to both E1A and TFIIA, it is intriguing to consider the possibility that by interacting with hTAF II 135, E1A stabilizes the TFIID-TFIIA complex to increase the level of activated transcription. It will be important to determine whether the C terminus of hTAF II 135 interacts with TFIIA or another cofactor which may play a role in E1A-mediated transactivation. In addition to the viral transactivators E1A, T antigen, and E7, the cellular activators SP1 and CREB have also been shown to bind hTAF II 135 (33) . However, unlike these viral transactivators, which all bind to the C terminus of hTAF II 135, SP1 and CREB bind to a central region of hTAF II 135. The ability of different activators to interact with distinct regions of hTAF II 135 could contribute to synergistically activated transcription, as in the case of the individual activator-TAF interactions described for Bicoid-dTAF II 110 and Hunchback-dTAF II 60 (31) .
How might interactions between CR3 of E1A and cellular transcription factors facilitate activated transcription? E1A, which does not specifically recognize DNA, apparently localizes to the promoter via interactions between transcription factors bound at sequence-specific DNA recognition sites, e.g., ATF-2 (19, 20) , and components of the basal transcription factor TFIID, which include TBP (7, 13, 17) , hTAF II 250 (6), hTAF II 55 (4), and hTAF II 135 (this study). This and previous studies suggest that different regions of the CR3 activation domain may contact specific factors of the TFIID complex, i.e., binding of the zinc finger to TBP and the zinc finger flanking regions to hTAF II 135. Such CR3 interactions could induce conformational changes or chemical modifications of TFIID subunits. Conceivably, E1A mediates transactivation by recruiting or enhancing the stability of TFIID binding to the promoter or by disrupting a negative interaction within the TFIID complex.
